TOPGEN provides tumor-oriented precision medical testing, cellular immunotherapy, and other services.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 13, 2020 | Series C | ¥120M | 3 | — | — | Detail |
Mar 16, 2017 | Post-IPO Equity | ¥25M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Zhujijingkaichuangrong Touzi | — | Series C |
Zhuji Jingkai Chuangyou Guquan Jijin | — | Series C |
Shanghai Hantai Chuangye Touzi | — | Series C |
Guoke Zhengdao Investment | — | Post-IPO Equity |